药物、药物、药物：囊性纤维化气道感染的当前治疗模式。
Drugs, Drugs, Drugs: Current Treatment Paradigms in Cystic Fibrosis Airway Infections.
机构信息
Department of Pediatrics, University of Washington , Seattle, Washington, USA.
Seattle Children's Research Institute, Seattle, Washington , USA.
出版信息
J Pediatric Infect Dis Soc. 2022 Sep 7;11(Supplement_2):S32-S39. doi: 10.1093/jpids/piac061.
Airway infections have remained a prominent feature in persons living with cystic fibrosis (CF) despite the dramatic improvements in survival in the past decades. Antimicrobials are a cornerstone of infection management for both acute and chronic maintenance indications. Historic clinical trials of antimicrobials in CF have led to the adoption of consensus guidelines for their use in clinical care. More recently, however, there are efforts to re-think the optimal use of antimicrobials for care with the advent of novel and highly effective CF transmembrane conductance regulator modulator therapies. Encouragingly, however, drug development has remained active concurrently in this space. Our review focuses on the evidence for and perspectives regarding antimicrobial use in both acute and maintenance settings in persons with CF. The therapeutic innovations in CF and how this may affect antimicrobial approaches are also discussed.
尽管在过去几十年中生存状况有了显著改善，但气道感染仍然是囊性纤维化（CF）患者的一个突出特征。抗生素是治疗急性和慢性维持期感染的基石。CF 抗生素的历史临床研究导致了共识指南的采用，以指导其在临床护理中的应用。然而，最近随着新型高效 CF 跨膜电导调节剂治疗药物的出现，人们正在努力重新思考抗生素的最佳使用方法。值得庆幸的是，在这方面药物研发仍然活跃。我们的综述重点关注 CF 患者在急性和维持期使用抗生素的证据和观点。还讨论了 CF 中的治疗创新以及这可能如何影响抗生素方法。
Zotero 插件